Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for BioMarin Pharmaceutical Inc. (BMRN : NSDQ)
 
 • Company Description   
BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder), Vimizim , Brineura, Palynziq and Voxzogo. BioMarin has a collaboration agreement with Sanofi's subsidiary Genzyme for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.?The newest drug in BioMarin's portfolio, Voxzogo for treating achondroplasia, the most common form of dwarfism. BioMarin's biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA.

Number of Employees: 3,045

 
 • Price / Volume Information   
Yesterday's Closing Price: $79.28 Daily Weekly Monthly
20 Day Moving Average: 1,263,382 shares
Shares Outstanding: 184.99 (millions)
Market Capitalization: $14,666.43 (millions)
Beta: 0.41
52 Week High: $94.20
52 Week Low: $71.59
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -1.52% 10.93%
12 Week 2.50% 12.69%
Year To Date -10.27% 9.64%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
770 Lindaro Street
-
San Rafael,CA 94901
USA
ph: 415-506-6700
fax: 415-382-7889
ir@bmrn.com http://www.bmrn.com
 
 • General Corporate Information   
Officers
Jean-Jacques Bienaime - Chairman and Chief Executive Officer
Brian R. Mueller - Executive Vice President; Finance & Chief Financia
Mark J. Alles - Director
Elizabeth McKee Anderson - Director
Willard H. Dere - Director

Peer Information
BioMarin Pharmaceutical Inc. (CORR.)
BioMarin Pharmaceutical Inc. (RSPI)
BioMarin Pharmaceutical Inc. (CGXP)
BioMarin Pharmaceutical Inc. (BGEN)
BioMarin Pharmaceutical Inc. (GTBP)
BioMarin Pharmaceutical Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 09061G101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 07/27/22
Share - Related Items
Shares Outstanding: 184.99
Most Recent Split Date: (:1)
Beta: 0.41
Market Capitalization: $14,666.43 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.19 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.94 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: 50.39% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/27/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 83.89
Trailing 12 Months: 264.27
PEG Ratio: 1.66
Price Ratios
Price/Book: 3.34
Price/Cash Flow: 91.71
Price / Sales: 7.80
EPS Growth
vs. Year Ago Period: 6.90%
vs. Previous Quarter: 247.62%
Sales Growth
vs. Year Ago Period: 6.86%
vs. Previous Quarter: 15.46%
ROE
03/31/22 - 1.36
12/31/21 - 1.32
09/30/21 - 2.02
ROA
03/31/22 - 0.97
12/31/21 - 0.94
09/30/21 - 1.44
Current Ratio
03/31/22 - 4.88
12/31/21 - 4.21
09/30/21 - 4.49
Quick Ratio
03/31/22 - 3.28
12/31/21 - 2.77
09/30/21 - 3.03
Operating Margin
03/31/22 - 3.10
12/31/21 - 3.02
09/30/21 - 4.57
Net Margin
03/31/22 - 2.09
12/31/21 - -3.47
09/30/21 - 0.86
Pre-Tax Margin
03/31/22 - 1.89
12/31/21 - -4.08
09/30/21 - -2.65
Book Value
03/31/22 - 23.74
12/31/21 - 23.26
09/30/21 - 23.24
Inventory Turnover
03/31/22 - 0.62
12/31/21 - 0.64
09/30/21 - 0.66
Debt-to-Equity
03/31/22 - 0.25
12/31/21 - 0.25
09/30/21 - 0.25
Debt-to-Capital
03/31/22 - 19.74
12/31/21 - 20.17
09/30/21 - 20.17
 

Powered by Zacks Investment Research ©